(COCP) Cocrystal Pharma, Inc. Business Model Canvas Research

Cocrystal Pharma, Inc. works with InterX Inc. on drug discovery, and the deal’s value is not publicly disclosed. The partnership helps widen Cocrystal Pharma, Inc.’s research output and pipeline reach by adding outside scientific capacity without building all of it in-house.

• Expands discovery capacity
• Supports pipeline growth
• Lowers internal strain

Cocrystal Pharma, Inc. relies on CRO and research service vendors for preclinical testing, assay development, and lab operations, so it can keep its own team lean while accessing specialist tools and GLP-capable work. This model fits biotech, where one drug program can need multiple outside partners across discovery, testing, and development.

• Outsource specialized lab work
• Support preclinical studies
• Speed assay and ops tasks
• Limit in-house fixed costs

Cocrystal Pharma, Inc. is advancing non-nucleoside polymerase inhibitors for norovirus and also holds licensed coronavirus work, so this key activity spans 2 major viral targets and broadens the antiviral pipeline. The focus is on RNA polymerase blocking, a core step in viral replication.

• Norovirus polymerase inhibitors
• Licensed coronavirus programs
• Broader antiviral pipeline

Cocrystal Pharma manages partnered research and licensing across Merck, Kansas State, HitGen, and InterX, so its pipeline depends on tight coordination, milestone tracking, and IP control. One missed term can slow data flow or weaken licensing rights.

• 4 active collaboration links

• Focus: pipeline execution

• Focus: intellectual property control

Cocrystal Pharma, Inc.'s structure-based technology platform is a core asset, letting it design antivirals by mapping viral protein shapes instead of relying on broad screening. That focus spans multiple virus families and helps the Company stand out in a field where many rivals chase hits first and specificity later.

• Rational design across virus families
• Core differentiator vs broad-screening rivals
• Supports faster, more targeted discovery

Cocrystal Pharma, Inc. is headquartered in Bothell, Washington, and this site anchors its corporate, scientific, and administrative work. In FY2025, that local base supports day-to-day R&D coordination, vendor access, and ties to the Seattle-area biotech labor pool.

One line: the Bothell headquarters is the control point for the business.

• Bothell, Washington base
• Supports R&D and admin
• Links to regional biotech talent
• Helps manage vendor work

Cocrystal Pharma, Inc. has clinical-stage HCV proof points: CC-31244 completed Phase IIa, showing the pipeline can move beyond early discovery into human efficacy testing. That kind of milestone matters because it lowers technical risk and can strengthen partner confidence in the antiviral platform.

• CC-31244 reached Phase IIa
• Shows clinical-stage execution
• Supports partner trust in platform

Cocrystal Pharma, Inc. builds antiviral compounds that can be licensed or co-developed, so larger drug makers can tap external innovation without starting from zero. That fit is clear in biotech partnering: Cocrystal’s model turns early-stage science into deal-ready assets, which matters when Big Pharma keeps buying rather than building every program in-house.

• License-ready antiviral pipeline
• Supports co-development deals
• Attracts external innovation buyers

Scientific data exchange is central to Cocrystal Pharma, Inc.’s research collaborations, because antiviral discovery depends on fast technical feedback on assay results, hit validation, and lead optimization. Ongoing data sharing helps the Company decide which compounds move forward and which stop early, reducing wasted lab work and speeding pipeline choices.

• Supports compound selection
• Tracks antiviral assay results
• Improves go-or-stop decisions

Cocrystal Pharma, Inc. uses public-market updates to keep investors informed, support trading liquidity, and help preserve access to capital for R&D. As a Nasdaq-listed biotech, its SEC filings and earnings updates matter because research programs are cash-heavy and outside funding can shape trial pace.

• Investor updates support capital access
• Public disclosure raises company visibility
• R&D funding depends on market confidence

Partner network referrals matter for Cocrystal Pharma, Inc. because alliances with Merck, Kansas State, HitGen, and InterX can widen reach and create warm introductions to new biotech partners. In biotech, referral-led access is often faster than cold outreach, especially when deal flow depends on trust and prior validation.

• Existing alliances expand visibility.
• Warm intros can speed partnering.
• Trust matters in biotech deals.

Cocrystal Pharma, Inc. uses peer-reviewed science and IP disclosures to prove its antiviral platform and keep partners informed; in its latest SEC filings, the Company reported no product revenue and continued to fund R&D, so credibility and patent signals matter for deal flow and hiring.

• Peer-reviewed data builds trust
• Patent filings signal platform depth
• Helps attract partners and talent

Government and public health stakeholders matter because Cocrystal Pharma, Inc.'s influenza and coronavirus antiviral programs fit outbreak readiness needs. The WHO still lists influenza and COVID-19 as ongoing global threats, and public buyers can support clinical work, stockpiling, or adoption when pandemic risk rises.

• Influenza and coronavirus have clear public health use cases
• Government support can speed trials and access
• Preparedness demand rises during outbreaks

Specialty antiviral development teams focused on HCV, influenza, norovirus, and coronavirus are direct buyers for Cocrystal Pharma, Inc. They want targeted, mechanism-based compounds, and Cocrystal’s antiviral pipeline is built for that need, with multiple programs aimed at high-burden viral diseases and faster path-to-clinic use cases.

• Focus: HCV, flu, norovirus, coronavirus
• Buyers want mechanism-based compounds
• Pipeline matches antiviral R&D demand

Cocrystal Pharma, Inc. keeps IP and licensing spend inside R&D and G&A, and its FY2025 filing does not show a separate line item for these costs. That means legal, patent, and collaboration fees are part of the asset base that supports its antiviral pipeline, not a standalone expense bucket.

In practice, the cost profile is tied to maintaining patents and managing partner deals, so the spend scales with the number of active programs and agreements.

• FY2025: no separate IP/licensing line disclosed
• Costs sit in R&D and G&A
• Support patents and partner agreements

Cocrystal Pharma, Inc. carries steady public-company overhead for headquarters, finance, reporting, and governance, plus SEC filing, audit, legal, and board compliance work. These costs do not stop when product sales are light, so they keep corporate operations running and investor reporting on track.

• HQ and finance staff
• SEC filings and compliance
• Audit, legal, and governance

Cocrystal Pharma, Inc. can earn royalties if licensed antivirals reach commercial sales, giving it long-term upside without running manufacturing or inventory. In biotech, royalty deals are usually a standard revenue stream and often land in the single-digit % range, while Cocrystal’s latest filings still show no royalty income, so this remains future optionality.

• Future sales can bring royalty cash
• No manufacturing needed
• Standard biotech monetization path

Cocrystal Pharma can use option and access fees to charge partners for early evaluation rights, target review, or data access before a license is signed. For a pre-commercial biotech, even small upfront fees can help fund R&D and reduce dilution while the platform is still being validated.

• Monetizes targets before product launch
• Funds early collaboration work
• Signals partner interest with low risk